Arto A Palmu
Overview
Explore the profile of Arto A Palmu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
797
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Finn A, Guiso N, Wirsing von Konig C, Martinon-Torres F, Palmu A, Bonanni P, et al.
Expert Rev Vaccines
. 2025 Mar;
24(1):175-182.
PMID: 40042539
Introduction: Pertussis vaccination in pregnancy is a safe and highly effective strategy to protect young infants against severe pertussis, but cases continue to occur. In November 2023, the authors of...
2.
Gehrt L, Moller S, Englund H, Laake I, Nieminen H, Feiring B, et al.
J Infect
. 2025 Jan;
90(2):106365.
PMID: 39788159
Objectives: To investigate if receipt of measles-mumps-rubella (MMR) vaccine following the third dose of diphtheria-tetanus-acellular pertussis (DTaP3) is associated with reduced rates of non-targeted infectious disease hospitalisations. Methods: Register based...
3.
Nieminen T, Palmu A, Auvinen R, Kulathinal S, Auranen K, Syrjanen R, et al.
Clin Epidemiol
. 2024 Dec;
16:901-915.
PMID: 39691210
Purpose: We developed a hybrid safety surveillance approach for a large, pragmatic clinical trial of a high-dose quadrivalent influenza vaccine (QIV-HD), using both active and passive data collection methods. Here,...
4.
Flem E, Mouawad C, Palmu A, Platt H, Johnson K, McIntosh E, et al.
Expert Rev Vaccines
. 2024 Oct;
23(1):997-1010.
PMID: 39435466
Introduction: Infant immunization programs using pneumococcal conjugate vaccines (PCVs) have reduced the rates of pneumococcal disease through direct vaccine-induced protection in vaccinated children and through indirect protection in non-vaccinated children...
5.
Saukkoriipi A, de Monerri N, Toropainen M, Lindholm L, Veijola R, Toppari J, et al.
Lancet Microbe
. 2024 Apr;
5(7):689-696.
PMID: 38679040
Background: Group B streptococcus is a major cause of neonatal disease. Natural history studies have linked maternally transferred anti-group B streptococcus capsular polysaccharide antibodies with protection against infant group B...
6.
Palmu A, Pepin S, Syrjanen R, Mari K, Mallett Moore T, Jokinen J, et al.
Influenza Other Respir Viruses
. 2024 Apr;
18(4):e13270.
PMID: 38569647
Background: We assessed the relative vaccine effectiveness (rVE) of high-dose quadrivalent influenza vaccine (QIV-HD) versus standard-dose quadrivalent influenza vaccine (QIV-SD) in preventing respiratory or cardiovascular hospitalizations in older adults. Methods:...
7.
Ekstrom N, Leino T, Juutinen A, Lehtonen T, Haveri A, Liedes O, et al.
Vaccines (Basel)
. 2024 Mar;
12(3).
PMID: 38543881
Data on immune responses following COVID-19 booster vaccinations and subsequent infections in the immunocompromised are limited. We studied antibody responses after the fourth dose and subsequent infections to define patient...
8.
Nieminen T, Auranen K, Kulathinal S, Harkanen T, Melin M, Palmu A, et al.
PLoS One
. 2023 Jun;
18(6):e0282094.
PMID: 37352274
In Finland, the first wave of the COVID-19 epidemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) took place from March to June 2020, with the majority of...
9.
Solastie A, Nieminen T, Ekstrom N, Nohynek H, Lehtonen L, Palmu A, et al.
Emerg Microbes Infect
. 2023 Jun;
12(2):2222849.
PMID: 37289188
Studying the prevalence of SARS-CoV-2 specific antibodies (seroprevalence) allows for assessing the impact of epidemic containment measures and vaccinations and estimating the number of infections regardless of viral testing. We...
10.
Hovi P, Palmu A, Nieminen T, Artama M, Jokinen J, Ruokokoski E, et al.
PLoS One
. 2023 Feb;
18(2):e0282226.
PMID: 36827275
Safe vaccination is essential for mitigation of the COVID-19 pandemic. Two adenoviral vector vaccines, ChAdOx1 nCov-19 (AstraZeneca) and Ad26.COV2.S (Johnson&Johnson/Janssen) have shown to be effective and they are distributed globally,...